VOSEVI (sofosbuvir) Patient Assistance Program
Don’t let the high cost of brand DAA-experienced chronic hepatitis C therapy disrupt your treatment. We help eligible patients access Vosevi (sofosbuvir/velpatasvir/voxilaprevir) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Vosevi (sofosbuvir/velpatasvir/voxilaprevir) is a once-daily, fixed-dose, three-DAA pan-genotypic regimen FDA-approved for chronic hepatitis C virus (HCV) re-treatment in adults previously treated with NS5A inhibitor or sofosbuvir-based DAA therapy who failed to achieve cure.
- Without assistance, Vosevi costs commonly run approximately $25,000–$28,000 per 28-day supply, with a typical 12-week course commonly $74,000–$84,000+.
- Through AffordMyPrescriptions, qualifying patients can access Vosevi for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- There is no generic Vosevi in the U.S. as of 2026. For first-line HCV cure, generic sofosbuvir/velpatasvir (Epclusa equivalent) or Mavyret are widely available pan-genotypic options at lower cost. Vosevi's role is specifically for retreating patients who failed prior DAA therapy.
What Is Vosevi Prescription Assistance Program?
The Vosevi Prescription Assistance Program is a manufacturer-sponsored initiative that provides Vosevi at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for chronic hepatitis C retreatment patients who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, hepatologist coordination, prior-DAA-treatment documentation, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and treatment-course completion.
Pharmacy Price Comparison
- Without assistance, Vosevi costs roughly $25,000–$28,000/month. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$27,000 | Save ~$26,930/mo |
| CVS Pharmacy | ~$28,000 | Save ~$27,930/mo |
| Walmart | ~$25,500 | Save ~$25,430/mo |
| Costco | ~$25,500 | Save ~$25,430/mo |
Specialty Pharmacy | ~$26,000 | Save ~$25,930/mo |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Vosevi Prescription Program?
The Patient Assistance Program is free to apply for and provides Vosevi at no medication cost if approved. Our $69.95/month service covers full advocacy.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Vosevi:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $25,000–$28,000 per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Vosevi assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Vosevi Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Vosevi:
Vosevi (sofosbuvir/velpatasvir/voxilaprevir) is a once-daily, fixed-dose, three-DAA pan-genotypic combination for chronic hepatitis C retreatment. It is specifically used for patients who have already received DAA therapy and failed to achieve sustained virologic response.
How Vosevi Works:
Vosevi is a retreatment regimen designed for hepatitis C patients who failed prior therapies due to resistance-associated substitutions (RAS) in the virus. It combines three distinct direct-acting antivirals: sofosbuvir, velpatasvir, and voxilaprevir. Together, these drugs target different viral proteins to overcome existing resistance patterns. This three-class combination achieves a cure rate of over 95% within a standard treatment window.
Form and use:
This medication is administered orally as a single tablet taken once every day. Patients must take the tablet with food to ensure proper absorption and effectiveness. The standard duration required for this retreatment course is exactly 12 weeks. The majority of patients are successfully cured after completing just one full course of therapy.
Generic availability:
As of 2026, there is no generic version of Vosevi available within the United States. While cheaper generic first-line options like Mavyret or sofosbuvir/velpatasvir exist, they are meant for initial treatment. Vosevi maintains a specific clinical niche exclusively for patients facing therapy failure. Its unique three-class composition provides the necessary advantage that standard first-line options lack.
Warnings:
Vosevi is strictly contraindicated and should not be used in patients who have severe hepatic impairment. Before starting therapy, patients must undergo hepatitis B testing to prevent severe or fatal HBV reactivation flares. There is a risk of serious bradycardia if this medication is taken concurrently with amiodarone. Additionally, it interacts negatively with strong P-gp/CYP inducers such as rifampin, carbamazepine, phenytoin, and St. John’s wort.
FAQ (Frequently Asked Questions)
How Much Does Vosevi Cost Without Insurance?
Vosevi costs approximately $25,000–$28,000 per 28-day supply. Through AffordMyPrescriptions, qualifying patients receive Vosevi at no medication cost — our $69.95 monthly fee covers full advocacy and program management
Why Is Vosevi Used For Retreatment Specifically?
Vosevi is the specifically FDA-approved retreatment regimen for patients who failed prior DAA therapy (Harvoni, Epclusa, Mavyret, or others). The three-class composition (NS5B + NS5A + NS3/4A) overcomes most resistance-associated substitutions that develop after first-line DAA failure. For first-line HCV cure, simpler two-drug combinations like Epclusa or Mavyret are used
Will I Be Cured After Vosevi Retreatment?
In most cases, yes. Vosevi achieves sustained virologic response 12 weeks after therapy (SVR12) in over 95% of retreatment patients across genotypes. SVR12 means HCV is undetectable 12 weeks after stopping treatment — considered durable cure.
What If I'm Treatment-Naïve — Can I Use Vosevi?
Vosevi is FDA-approved specifically for retreatment after DAA failure. Treatment-naïve patients are typically treated with Epclusa, Mavyret, or Harvoni first — these simpler two-DAA regimens cure over 95% of treatment-naïve patients and are generally less costly. If first-line therapy fails, Vosevi is then used for retreatment.
Can I Get Vosevi Through The PAP If I Have Medicare?
Yes. Medicare Part D beneficiaries can typically qualify, especially if you face specialty-tier copays you cannot afford for the duration of therapy.
What If I Have Hepatitis B Co-infection?
Tell your prescriber. HCV treatment with DAAs can cause severe hepatitis B reactivation in patients with chronic HBV. HBV testing is required before starting, and HBV co-infection requires a coordinated treatment plan.
What If My Application Is Denied?
If denied, we explore alternatives — Mavyret (also pan-genotypic, sometimes effective for retreatment), longer-duration combination therapy with ribavirin, state Medicaid for chronic HCV, the manufacturer’s copay program for commercially insured patients, or independent foundations. If we cannot find a path, you won’t be charged our service fee
Take Control of Your Medication Costs
If you are struggling with the high cost of Vosevi, our team may be able to help you access assistance programs designed to make brand HCV retreatment regimens affordable. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.